Propranolol Stats & Data

Propranolol is a non-selective beta-1/beta-2 blocker used for cardiovascular indications, migraine prophylaxis, essential tremor, thyrotoxicosis, infantile hemangioma, and off-label for performance anxiety. It is contraindicated in asthma/COPD and in patients with baseline bradycardia or higher-degree heart block due to risk of bronchospasm and conduction block. It can exacerbate peripheral vasospasm and is generally avoided in vasospastic (Prinzmetal) angina. In diabetes, propranolol may blunt adrenergic warning signs of hypoglycemia (e.g., tremor, palpitations), so glucose monitoring and education are essential. During acute cocaine toxicity, non-selective beta-blockers are generally avoided because of potential unopposed alpha-adrenergic vasoconstriction; tachycardia and hypertension should be managed with alternatives per emergency protocols. In known or suspected pheochromocytoma, do not start beta-blockade until adequate alpha-blockade is established; otherwise severe hypertension can occur. Combining propranolol with potent AV-nodal–blocking drugs (verapamil, diltiazem; digoxin; amiodarone) substantially increases risks of bradycardia, heart block, and hypotension; if used, it requires close monitoring and is often avoided. Propranolol can reduce responsiveness to epinephrine in anaphylaxis; this does not contraindicate epinephrine, but emergency teams may give glucagon as an adjunct if refractory. Abrupt discontinuation after chronic use can precipitate rebound tachycardia, angina, or myocardial infarction; taper gradually with prescriber guidance. Overdose can cause profound bradycardia, hypotension, hypoglycemia, seizures, and wide QRS from sodium-channel blockade; emergency care may involve glucagon, high-dose insulin-euglycemia therapy, vasopressors, sodium bicarbonate for QRS widening, and lipid emulsion in refractory cases. IV propranolol should only be used with continuous ECG and blood-pressure monitoring; non-medical IV use is hazardous. Lipophilicity means CNS effects (fatigue, sleep disturbance, vivid dreams/nightmares) are more likely than with hydrophilic beta-blockers; mood changes and depressive symptoms are reported but causality is mixed. Hepatic impairment and CYP2D6 inhibitors can raise levels; start low and titrate cautiously. During breastfeeding, transfer into milk is low and adverse infant effects are unlikely; this is considered compatible with lactation. Food increases oral bioavailability; dose timing consistency helps avoid variability in effect.